Piromelatine

TargetMol
Product Code: TAR-T34081
Supplier: TargetMol
CodeSizePrice
TAR-T34081-1mg1mg£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34081-5mg5mg£204.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34081-1mL1 mL * 10 mM (in DMSO)£217.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34081-10mg10mg£270.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34081-25mg25mg£414.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34081-50mg50mg£627.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34081-100mg100mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34081-500mg500mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Piromelatine(NEU-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals, which is an agonist at melatonin MT1/MT2 and serotonin 5-HT1A/5-HT1D receptors. Piromelatine has been shown that has analgesic, antihypertensive and cognitive benefits in rat disease models of pain, hypertension, and Alzheimer's disease in Pre-clinical studies.
CAS:
946846-83-9
Formula:
C17H16N2O4
Molecular Weight:
312.325
Pathway:
GPCR/G Protein|Membrane transporter/Ion channel|Neuroscience
Purity:
0.98
SMILES:
COc1ccc2[nH]cc(CCNC(=O)c3cc(=O)cco3)c2c1
Target:
Sodium Channel|MT Receptor|TRP/TRPV Channel|P2X Receptor|5-HT Receptor

References

Yuan-Yuan Liu, et al. Piromelatine Exerts Antinociceptive Effect via Melatonin, Opioid, and 5HT1A Receptors and Hypnotic Effect via Melatonin Receptors in a Mouse Model of Neuropathic Pain. Psychopharmacology (Berl). 2014 Oct;231(20):3973-85. L Huang, et al. Blood Pressure Reducing Effects of Piromelatine and Melatonin in Spontaneously Hypertensive Rats. Eur Rev Med Pharmacol Sci. 2013 Sep;17(18):2449-56. Meihua She, et al. Piromelatine, a Novel Melatonin Receptor Agonist, Stabilizes Metabolic Profiles and Ameliorates Insulin Resistance in Chronic Sleep Restricted Rats. Eur J Pharmacol. 2014 Mar 15;727:60-5. Schneider LS, et al. A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease. J Prev Alzheimers Dis. 2022;9(2):247-254.